Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...
Based on insights from Towards Packaging, the global cell therapy packaging market will likely grow from USD 419.57 million ...
To manage the finances of CAR-T therapies, which can cost up to $1 million each, health systems are increasingly using “pay for performance” deals, according to a Nov. 17 article in Specialty Pharmacy ...
CHICAGO — Positive phase 3 trials for two drugs, telitacicept and ianalumab, showed promise for offering systemic treatment for Sjögren disease, rather than only symptom control. Findings of both ...
ESRB Warns of Systemic Risks From Stablecoins, Crypto-Investment Products, and Multi-Function Groups
The European Systemic Risk Board (ESRB), which is responsible for collecting and analyzing data from national central banks, supervisors, and the European Union agencies about risk in the EU financial ...
An international study led by scientists at Flinders University and at South China University of Technology has uncovered a new vulnerability in prostate cancer cells that could help improve treatment ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Breakthrough Therapy ...
Warpage of dies, redistribution layers, and interposers is a growing problem in multi-chiplet packages, and it can have a dramatic impact on the behavior and reliability of these devices. Multiple ...
In the heart of downtown Rochester, nestled inside the Main Street Plaza, lies a sanctuary for those suffering from chronic digestive issues — the Natural Digestive Health Center, founded by Karyn ...
Researchers from Drexel University’s College of Arts and Sciences and College of Medicine have found a potential new therapeutic target for Alzheimer’s disease. Expanding on their previous research on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback